Are you Dr. Granoff?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 14 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
5700 Martin Luther King Jr Way
Oakland, CA 94609Phone+1 510-450-7640Fax+1 510-450-7915
Summary
- Dr. Dan Granoff, MD is a pediatric infectious disease specialist in Oakland, California. He is currently licensed to practice medicine in California, North Carolina, and Ohio. He is affiliated with UCSF Benioff Children's Hospital Oakland.
Education & Training
The MetroHealth System/Case Western Reserve UniversityResidency, Pediatrics, 1973 - 1975
Johns Hopkins UniversityResidency, Pediatrics, 1969 - 1971- Johns Hopkins University School of MedicineClass of 1971
Certifications & Licensure
CA State Medical License 1973 - 2026
NC State Medical License 1979 - 1990
MD State Medical License 1969 - 1980
OH State Medical License 1973 - 1979- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1987
Clinical Trials
- Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) Start of enrollment: 2015 Jan 01
Publications & Presentations
PubMed
- 1 citationsSerogroup B meningococcal disease in persons previously vaccinated with a serogroup B meningococcal vaccine - United States, 2014-2019.Heather Reese, Lucy A McNamara, Vianca Vianzon, Amy Blain, Nadav Topaz
Vaccine. 2021-11-13 - 7 citationsNeisseria meningitidis Urethritis Outbreak Isolates Express a Novel Factor H Binding Protein Variant That Is a Potential Target of Group B-Directed Meningococcal (MenB...Yih-Ling Tzeng, Serena Giuntini, Zachary Berman, Soma Sannigrahi, Dan M. Granoff
Infection and Immunity. 2020-11-16 - 12 citationsDifferential effects of therapeutic complement inhibitors on serum bactericidal activity against non-groupable meningococcal isolates recovered from patients treated w...Dan M. Granoff, Howard Kim, Nadav Topaz, Jessica R. MacNeil, Xin Wang
Haematologica. 2019-08-01
Press Mentions
- The Debate over Booster Shots for CovidSeptember 23rd, 2021
Meningitis B Vaccine Falls Short of ExpectationsJuly 20th, 2016
Personal HealthOctober 25th, 1990- Join now to see all
Grant Support
- An Engineered Meningococcal Omv Vaccine For Africa Against All Capsular GroupsNational Institute Of Allergy And Infectious Diseases2010–2012
- Novel Vaccine Strategies For Prevention Of N. Meningitidis Group B DiseaseNational Institute Of Allergy And Infectious Diseases2009–2011
- Novel Vaccine Approaches For N. Meningitidis DiseaseNational Institute Of Allergy And Infectious Diseases2004–2007
- Molecular Basis Meningococcal Group A Capsular ImmunityNational Institute Of Allergy And Infectious Diseases2004–2007
- Neisseria Meningitidis Antigens Expressed In InfectionNational Institute Of Allergy And Infectious Diseases2004–2005
- Men CNational Center For Research Resources2004–2005
- Men BNational Center For Research Resources2004–2005
- Men ANational Center For Research Resources2004
- Conserved Neisseria Proteins As Vaccine CandidatesNational Institute Of Allergy And Infectious Diseases2000–2002
- Mimetics Of Capsular Epitopes Of Neisseria MeningitidisNational Institute Of Allergy And Infectious Diseases2000–2001
- Genetic Control Of Antibody Responses To PolysaccharidesNational Institute Of Allergy And Infectious Diseases1993
- Neisseria Meningitidis Group B;Idiotypes And VaccinesNational Institute Of Allergy And Infectious Diseases1992
- Genetic Control Of Antibody Responses To PolysaccharidesNational Institute Of Allergy And Infectious Diseases1985–1991
- Outer Membrane Proteins Of Haemophilus Influenzae Type BNational Institute Of Allergy And Infectious Diseases1985
